Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Ta Wei Wu"'
Autor:
Min-Hua Tseng, Shih-Hua Lin, Wen-Lang Fan, Ta-Wei Wu, Shuan-Pei Lin, Jhao-Jhuang Ding, I-Jung Tsai, Jeng-Daw Tsai
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 6, Pp 647-654 (2024)
Background/Purpose: Congenital nephrotic syndrome (CNS) is one of the important causes of end-stage kidney disease in children. Studies on the genotype, phenotype, and clinical outcome in infants with CNS caused by genetic mutations are scarce. Metho
Externí odkaz:
https://doaj.org/article/1e170828760c4ebbb1c31b9c481d681c
Publikováno v:
Tzu-Chi Medical Journal, Vol 36, Iss 3, Pp 340-348 (2023)
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: PubMed, EMBASE, and th
Externí odkaz:
https://doaj.org/article/60c56a7e8675442a86e31385dfcfe2d6
Publikováno v:
Thoracic Cancer, Vol 14, Iss 30, Pp 3012-3019 (2023)
Abstract Background Cyclin‐dependent kinases 4 and 6 inhibitors (CDK4/6i) have been shown to improve progression‐free survival (PFS) in patients with metastatic breast cancer (MBC) in randomized control trials. This study aimed to evaluate the ef
Externí odkaz:
https://doaj.org/article/a3d7787227d64df88a4bf6317525d5e6
Publikováno v:
Thoracic Cancer, Vol 14, Iss 10, Pp 929-939 (2023)
Abstract Background To assess the efficacy and safety of anaplastic lymphoma kinase inhibitors (ALKIs) for the treatment of advanced‐stage ALK rearrangement‐positive non–small cell lung cancer (NSCLC). Methods We searched PubMed, EMBASE, and th
Externí odkaz:
https://doaj.org/article/337d13b71da146e9bba0d57baed9563c
Publikováno v:
BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background To ascertain the efficacy, safety, and immunogenicity from existing evidence via conducting a meta-analysis of randomized controlled trials between biosimilar and originator insulins. Methods The PubMed, Cochrane Library, EMBASE,
Externí odkaz:
https://doaj.org/article/1be271247237486a9c846d4962500cdf
Publikováno v:
Tzu-Chi Medical Journal, Vol 34, Iss 2, Pp 219-225 (2022)
Objectives: Transarterial chemoembolization (TACE) or sorafenib may prolong survival in patients with unresectable hepatocellular carcinoma (HCC); however, whether their combination prolongs survival than TACE alone remains controversial. We aimed to
Externí odkaz:
https://doaj.org/article/1ba0be0c8cdd4f9388e272df52b2469f
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2873-2885 (2021)
Abstract Objective Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non‐small‐cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety remain unclear. Methods We searched electronic databases
Externí odkaz:
https://doaj.org/article/5dc14e10311f40bb9623c659501186a8
Autor:
Chao-Chuan Wu, Chih-Wei Tseng, Kuo-Chih Tseng, Yen-Chih Chen, Ta-Wei Wu, Sou-Yi Chang, Yao-Jen Chang, You-Chen Chao, Ching-Sheng Hsu
Publikováno v:
Journal of the Formosan Medical Association, Vol 120, Iss 5, Pp 1249-1258 (2021)
Background/purpose: Radiofrequency ablation (RFA) is increasingly being used instead of surgical resection for the treatment of hepatocellular carcinoma (HCC) tumor measuring ≦2 cm. However, the long-term outcomes of RFA, especially in comparison t
Externí odkaz:
https://doaj.org/article/1fade2d2efcf4697bc7c56908320f6cb
Publikováno v:
Tzu Chi Medical Journal; Jul-Sep2024, Vol. 36 Issue 3, p340-348, 9p
Publikováno v:
American Journal of Therapeutics; May/Jun2024, Vol. 31 Issue 3, pe286-e297, 12p